Cannabidiol Cbd Articles & Analysis
25 news found
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
CanaQuest created a game-changing formula derived from cannabidiol "CBD" + IP formula. It has a Drug Candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
Hunter Land, CSO of Neeka, who co-led the clinical development of Epidiolex® (FDA approved prescription CBD) for GW Pharma will lead all studies for Neeka and CanaQuest. Dr. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol ...
Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, ...
Researchers examined the role of the cannabinoid cannabidiol (CBD) in communication between cells, in particular its potential to increase death of glioblastoma cells in response to radiation therapy—without causing similar cell death in normal brain cells. ...
Published Preclinical Data Shows KLS-13019 More Effective Than Cannabidiol (CBD) in Prevention, Reversal of Chemotherapy-Induced Peripheral Neuropathy (CIPN) DOYLESTOWN, PA – April 13, 2022 – Neuropathix, Inc. ...
This patent award in India furthers our standing as a leader and pioneer in the discovery and preclinical testing of novel globally patented synthetic analogues of cannabidiol (CBD). We believe that the general consensus regarding our position in the market will ultimately turn to the fact that our IP has taken the best that nature has offered which is ...
We knew their expertise in the bulk synthesis of cannabidiol (CBD) would be a game changer then. So back then, we decided to put the Purisys highly purified, pharmaceutical grade synthetic CBD together with our proprietary compound NPTX-204, into a gel capsule formulation under a feasibility and stability study at Catalent Pharma Solutions. ...
What makes LEA™ unique and effective is its novel chemical properties which have outperformed CBD and tacrolimus in preclinical studies. We now move into the commercial phase of development for LEA™ and, as such, we have now formed Dermique to capitalize on LEA™ as well as the underlying brands we intend to bring to the market for a variety of disorders and skin ...
“A few years ago we were asked if we had a compound to treat radiation dermatitis, a significant problem for patients undergoing chemotherapy and radiation treatments for breast cancer. Of the CBD analogues that we developed, we felt that LEA™ was best to test in parallel with cannabidiol and tacrolimus. ...
What is the Difference Between CBDA and CBD? Now that CBD has been federally legal for a few years, you might be familiar with the differences between CBD and THC—the other most commonly known natural compound in the cannabis plant. ...
ByMedcbdx
Each one has a different effect on the body, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the main chemicals used in ...
W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. ...
The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6. ...
(“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in ...
(“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in ...
According to a recent report, the global skin care products market size is projected to reach $183.03 billion USD by 2025.1 “We are currently testing the anti-inflammatory and antioxidant potential of our patented compound Atopidine™ versus Betamethasone, a well-known corticosteroid and cannabidiol (CBD). When these studies are completed, we believe ...
The study was performed by Kannalife and the Lewis Katz School of Medicine at Temple University (LKSOM) to assess KLS-13019, the Company’s patented cannabidiol (CBD)-like molecule as a potential treatment of neuropathic pain and drug dependence. ...